Ronald Rubenstein
Division Chief, Division of Allergy, Immunology & Pulmonary Medicine · Washington University/B-JH/SLCH Consortium
Credentials: · · · · ·
History
PresentDivision of Allergy · Washington University/B-JH/SLCH Consortium
Research
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
New England Journal of Medicine · 2010 · 629 citations
Thorax · 2012 · 420 citations
Journal of Clinical Investigation · 1997 · First of 3 authors · Corresponding · 321 citations
15 papers
12 papers
10 papers
10 papers
9 papers
8 papers
6 papers
5 papers · 3 as a fellow
Grants
- 2017–2021
erp29: Promoting Ion Channel Biogenesis from the Er Lumen
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.7M · Washington University
- 2000–2014
DeltaF508-CFTR Trafficking Regulated by 4-Phenylbutyrate
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.5M · Children's Hosp of Philadelphia
- 2009–2011
Regulatory Interactions of CFTR and ENaC
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $822.5K · Children's Hosp of Philadelphia
- 2004–2006
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $31.4K · Children's Hosp of Philadelphia
Clinical trials
- 2003–2019
Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis
Principal investigator · Completed
Children's Hospital of Philadelphia
- 2003–2008
Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)
Principal investigator · Terminated · Phase 1, Phase 2
Children's Hospital of Philadelphia
- 2001–2005
Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)
Principal investigator · Completed · Phase 1, Phase 2
Children's Hospital of Philadelphia